Advanced search×

This Week in JAMA

Author(s) unavailable

JAMA 306(5):461 (2011)

DOI: 10.1001/jama.2011.1081
Version: za2963e q8za1 q8zb6 q8zc1 q8zda q8zea q8zff q8zgb
Buy PDF

Similar articles you may find interesting…

  1. Delay in Surgical Treatment and Survival After Breast Cancer Diagnosis in Young Women by Race/Ethnicity.
    Erlyn C Smith, Argyrios Ziogas, and Hoda Anton-Culver

    JAMA Surgery (2013) PMID 23615681

    IMPORTANCE Breast cancer in women between the ages of 15 and 39 years (adolescents and young adults [AYAs]) constitutes 5% to 6% of all breast cancer cases in the United States. Breast cancer in AYA women has a worse prognosis than in older women. Five-year survival rates are lowest...
    Buy PDF
  2. Treatment of Neural Anosmia by Topical Application of Basic Fibroblast Growth Factor-Gelatin Hydrogel in the Nasal Cavity: An Experimental S...
    Jumpei Nota, Hirotaka Takahashi, and Kiyofumi Gyo

    JAMA Otolaryngology - Head & Neck Surgery 139(4):396-400 (2013) PMID 23599076

    IMPORTANCE A new treatment of neural anosmia. OBJECTIVE To investigate the effects of basic fibroblast growth factor (bFGF)-gelatin hydrogel on recovery of neural anosmia in mice. DESIGN Anosmia was induced by intraperitoneal injection of 3-methylindole, 200 mg/kg. One week later, th...
    Buy PDF
  3. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 he...
    Eric Lawitz, Jay P Lalezari, and Andrew Muir

    Lancet Infect Dis (2013) PMID 23499158

    In cohort A, 122 patients were assigned 200 mg sofosbuvir (48 patients), 400 mg sofosbuvir (48), or placebo (26). We enrolled 25 patients into cohort B. The most common adverse events-fatigue, headache, nausea, and chills-were consistent with those associated with peginterferon and ribavirin. Eight...
    Buy PDF